Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer

Area of Science:

• Molecular Biology
• Cancer Biology
• Genetics

Background:

• Alternative splicing (AS) generates multiple transcripts from a single gene, influencing cellular functions.
• Aberrant AS is implicated in cancer, producing proteins that drive tumor growth, invasion, and metastasis.
• The DMP1-ARF-MDM2-p53 pathway is crucial in cancer, with its components subject to aberrant splicing.

Purpose of the Study:

• To review the role of aberrant alternative splicing in the DMP1-ARF-MDM2-p53 pathway in cancer.
• To highlight how specific splice variants contribute to tumorigenesis and patient outcomes.
• To explore the potential of targeting oncogenic splice variants for cancer therapy.

Main Methods:

• Literature review focusing on aberrant splicing in the DMP1-ARF-MDM2-p53 pathway.
• Analysis of studies investigating the functional impact of splice variants on cancer progression.
• Examination of clinical data correlating splice variant expression with patient survival.

Main Results:

• The DMP1 locus produces tumor-suppressive DMP1α and oncogenic DMP1β variants; increased DMP1β/α ratio correlates with breast cancer progression and poor survival.
• ARF is frequently inactivated by aberrant splicing in human cancers.
• MDM2 splice variants promote cell growth and tumorigenesis, associated with advanced cancer stages and metastasis.
• p53 locus produces isoforms impacting patient survival, with N-terminal variants (Δ40, Δ133) having negative effects and C-terminal variants (β/γ) having favorable effects.

Conclusions:

• Aberrant alternative splicing of key genes in the DMP1-ARF-MDM2-p53 pathway contributes significantly to cancer development and progression.
• Oncogenic splice variants, often specific to cancer cells, represent promising therapeutic targets.
• Targeting these cancer-specific splice variants could lead to novel molecular therapies for various malignancies.